ライフサイエンスコーパス: formoterol

1 milast N-oxide) each sensitized to the LABA, formoterol.

2 received placebo were switched to budesonide/formoterol.

3 oterol, dexamethasone, or dexamethasone plus formoterol.

4 n of GRE-dependent transcription by the LABA formoterol.

5 ontrol measures generally favored budesonide/formoterol.

6 tiomers) of beta(2)AR agonists, albuterol or formoterol.

7 steroid or by whether the patient was taking formoterol.

8 rmoterol 400/12 mug twice daily + budesonide/formoterol 200/6 mug as needed for 12 weeks.

9 up consisted of two actuations of budesonide-formoterol (200 mug and 6 mug, respectively, per actuati

10 up consisted of two actuations of budesonide-formoterol (200 mug and 6 mug, respectively, per actuati

11 randomly assigned inhaled placebo or inhaled formoterol 24 micrograms bid for 4 weeks each in a cross

12 2 of 621 who started) were randomly assigned formoterol 4.5 microg or terbutaline 0.5 mg as needed by

13 When taken as needed, formoterol 4.5 microg provided better asthma control tha

14 ith twice-daily ICS/LABA therapy (budesonide/formoterol 400 mug/12 mug; Turbuhaler).

15 eeks and maintenance therapy with budesonide/formoterol 400/12 mug twice daily + budesonide/formotero

16 gic receptors with salbutamol (40 microm) or formoterol (5 microm) resulted in significant enhancemen

17 eatment period by use of cumulative doses of formoterol (6-108 micrograms) with FEV1 and FEF25-75 mea

18 Our behavioral analyses revealed that formoterol, a long-acting beta2 adrenergic receptor agon

19 mportant, OPG-Fc combined with a low dose of formoterol, a member of a new generation of beta2-agonis

20 We recently showed that formoterol, a potent, highly specific, and long-acting b

21 Budesonide/formoterol administration led to a significant improveme

22 icate that the unique structural features of formoterol allow it to interact with the beta2AR to acti

23 Formoterol and albuterol were equally efficacious.

24 curred in 0 and 4 patients in the budesonide/formoterol and budesonide groups, respectively.

25 act infection (5.8% and 4.4%) for budesonide/formoterol and budesonide, respectively.

26 While formoterol and clenbuterol increased cAMP, only formoter

27 to these differences in signaling, we docked formoterol and clenbuterol to six structures of the beta

28 s formoterol with fixed-dose budesonide plus formoterol and fixed-dose fluticasone plus salmeterol fo

29 lbuterol, and the long-acting beta2-agonists formoterol and olodaterol.

30 Recently, a direct interaction between formoterol and protein phosphatase 2A (PP2A) has been de

31 Formoterol and salbutamol also showed anti-inflammatory

32 The beta2 adrenoceptor agonists formoterol and salbutamol mediated suppression of IL-27p

33 nutes: mean difference at 60 minutes between formoterol and salmeterol in total airway resistance at

34 docyanopindolol-labeled bronchial membranes, formoterol and salmeterol induced high-affinity states o

35 The twice-daily beta2-agonists formoterol and salmeterol represent important advances.

36 Formoterol and salmeterol were highly selective for the

37 ught to identify the MB signaling pathway of formoterol and the differences in signaling between thes

38 The long-acting beta(2)-agonist formoterol and the glucocorticoid dexamethasone signific

39 ximum and 6 h) after placebo with that after formoterol, and expressed this degree as a percentage of

40 4 weeks' treatment with the beta2-AR agonist formoterol, and was not ablated by mTOR inhibition.

41 ctivation of the beta2AR increased invasion (formoterol area under the curve [AUC] relative to vehicl

42 n FEV1 increased by 260 ml in the budesonide/formoterol arm compared with 5 ml in the placebo arm (P

43 ed to investigate the durations of action of formoterol at beta 1-adrenoceptors and of salmeterol at

44 which was dependent on the cAMP/Ca(2+) loop (formoterol AUC in the presence of 2'5'-dideoxyadenosine

45 ly intraperitoneal injection with vehicle or formoterol beginning 24 hours after surgery and continui

46 o short-acting (salbutamol) and long-acting (formoterol) beta2 -agonists.

47 e taken before and after 8 wk treatment with formoterol, budesonide, or placebo from atopic asthmatic

48 r to change control medication to budesonide/formoterol combination (BUD/FM) 320/9 mug/day or to keep

49 y results occurred after chronic dosing with formoterol compared with salmeterol.

50 and efficacy of the long-acting beta-agonist formoterol compared with terbutaline, each taken as need

51 d the duration of gene expression induced by formoterol, dexamethasone, or dexamethasone plus formote

52 Twenty-five patients received budesonide/formoterol during the study.

53 adenylyl cyclase, namely epinephrine > or = formoterol = fenoterol > terbutaline = zinterol = albute

54 ctivity of other beta2-agonists (salbutamol, formoterol, fenoterol, clenbuterol, or adrenaline).

55 ated combination therapy with budesonide and formoterol for both maintenance and relief of symptoms.

56 ved beclometasone dipropionate (100 mug) and formoterol fumarate (6 mug) in two actuations twice dail

57 compared with beclometasone dipropionate and formoterol fumarate (BDP/FF) treatment.

58 eliever (SMART) regimen (with budesonide and formoterol fumarate), and anti-IgE therapy.

59 t with extrafine beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/

60 e formulation of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/

61 Patients taking formoterol had a longer time to their first severe asthm

62 irway epithelia, roflumilast interacted with formoterol in a positive cooperative manner to enhance t

63 than eight actuations per day of budesonide-formoterol in addition to the four maintenance doses in

64 e potencies and efficacies of salmeterol and formoterol in humans.

65 Early treatment with inhaled budesonide/formoterol in patients at risk for acute respiratory dis

66 l, two indacaterol analogues, salmeterol and formoterol) in monounsaturated model membranes using mag

67 Only formoterol increased cGMP.

68 moterol and clenbuterol increased cAMP, only formoterol increased the phosphorylation of Akt and its

69 me distributions for each state reveals that formoterol increases the frequency of activation transit

70 Formoterol induced MB as measured by increases in uncoup

71 beta-2 adrenergic receptor (beta2AR) agonist formoterol induces mitochondrial biogenesis (MB), but ot

72 fficacy and safety of combination budesonide/formoterol inhaler according to a single inhaler regimen

73 The Single combination budesonide-formoterol inhaler Maintenance And Reliever Therapy (SMA

74 d to clenbuterol, the methoxyphenyl group of formoterol interacted more frequently with V114 and F193

75 In this cell line, formoterol, like the nonselective beta-adrenoceptor agon

76 data set from 3 studies comparing budesonide/formoterol maintenance and reliever therapy with fixed-d

77 cs were randomly assigned to budesonide plus formoterol maintenance and reliever therapy, fixed-dose

78 The effect of budesonide/formoterol on the FEV1 was maintained in the 13 patients

79 s with mild/severe BOS to receive budesonide/formoterol or placebo for 6 months.

80 ositive effects on cognition in Ts65Dn mice, formoterol or similar beta2 adrenergic receptor agonists

81 th salmeterol (OR, 1.7 [CI, 1.1 to 2.7]) and formoterol (OR, 3.2 [CI, 1.7 to 6.0]) and in children (O

82 reliever therapy, fixed-dose budesonide plus formoterol, or fixed-dose fluticasone plus salmeterol fo

83 D while receiving treatment with salmeterol, formoterol, or salbutamol.

84 r FEF(25-75), were significantly better with formoterol over the entire 60 minutes: mean difference a

85 6 +/- 0.32), increased intracellular Ca(2+) (formoterol pEC50 8.20 +/- 0.33) and reduced phosphorylat

86 beta2AR activation results in elevated cAMP (formoterol pEC50 9.86 +/- 0.32), increased intracellular

87 0.33) and reduced phosphorylated ERK (pERK; formoterol pIC50 11.62 +/- 0.31).

88 ized 1:1 to 320/9 mug twice-daily budesonide/formoterol pMDI or 320 mug twice-daily budesonide pMDI.

89 In this population budesonide/formoterol pMDI was well tolerated over 12 months, with

90 safety and asthma control with a budesonide/formoterol pressurized metered-dose inhaler (pMDI) versu

91 Therefore, it seemed that formoterol relied on its moderately lipophilic nature to

92 h duration of action, whereas salmeterol and formoterol require twice-daily administration.

93 Treatment with formoterol restored renal function, rescued renal tubule

94 s unique to beta 2-adrenoceptors or, as with formoterol, resulted from its lipophilic nature and part

95 igands show that binding of the full agonist formoterol shifts the conformational distribution in fav

96 mug of small-particle hydrofluoroalkane 134a-formoterol solution or 50 mug of large-particle salmeter

97 Concomitantly, formoterol stimulated mitochondrial biogenesis and resto

98 montelukast (Singulair), and (4) budesonide/formoterol (Symbicort).

99 suggest that the ability of roflumilast and formoterol to interact in this way supports the concept

100 After formoterol treatment there was a significant decrease in

101 Salmeterol and formoterol, two new long-acting beta 2-agonists were equ

102 t-treatment year) were lower with budesonide/formoterol versus budesonide (incidence, 7.7% vs 14.0% [

103 rbation was longer (P= .018) with budesonide/formoterol versus budesonide.

104 Aerosolized budesonide/formoterol versus placebo bid for up to 5 days.

105 were significantly greater improvements with formoterol versus salmeterol in all IOS outcomes and FEF

106 eriments, cAMP responses to isoprenaline and formoterol waned with increasing numbers of washing proc

107 Postmortem analyses revealed that the use of formoterol was associated with a significant improvement

108 response element-dependent transcription by formoterol was displaced to the left by PDE4, but not PD

109 Formoterol was more efficacious (86 +/- 5%) than salmete

110 nd high doses of budesonide with and without formoterol were compared in patients with asthma.

111 red an adjustable regimen of budesonide plus formoterol with fixed-dose budesonide plus formoterol an